Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNuformix Regulatory News (NFX)

Share Price Information for Nuformix (NFX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.175
Bid: 0.17
Ask: 0.18
Change: -0.01 (-5.41%)
Spread: 0.01 (5.882%)
Open: 0.185
High: 0.00
Low: 0.00
Prev. Close: 0.185
NFX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of Meeting and Completion of Acquisition

13 Oct 2017 12:35

RNS Number : 5839T
Levrett PLC
13 October 2017
 

Levrett plc

 

GM Results and Completion of Acquisition of Nuformix Limited

 

13 October 2017

 

The board of Levrett plc ("Levrett" or "the Company") is pleased to announce the results of the general meeting of the Company held today in connection with (amongst other matters):

 

· the proposed acquisition of the entire issued share capital of Nuformix Limited ("Nuformix") for a total consideration of £12,000,000 to be settled through the issuance of new ordinary shares in the Company at a price of 4 pence per share ("Consideration Shares") (the "Acquisition"), subject to Shareholders' approval and re-admission to listing of its enlarged share capital to the standard listing segment of the Official List and to trading on the London Stock Exchange's Main Market ("Re-admission"); and

 

· a placing, under which the Company will issue 57,500,000 Placing Shares at 4p per share ("Placing Shares"), to raise £2.3 million, conditional, inter alia, upon Re-Admission (the "Placing").

 

At the general meeting of the Company, the resolutions proposed in connection with the Acquisition, the Placing and other matters, as set out in the prospectus to shareholders dated 15 September 2017 (the "Prospectus"), were duly passed on a show of hands in respect of Resolution 1, 2, 4, 5 and 6 and by way of a poll in respect of Resolution 3 as follows:

 

· Resolution 1 - to approve the Acquisition (as defined in the Prospectus);

 

· Resolution 2 - to authorise the directors to allot relevant equity securities up to an aggregate nominal amount of £519,250.00;

 

· Resolution 3 - to approve the waiver of any obligation which might otherwise arise under Rule 9 of UK City Code on Takeovers and Mergers;

 

· Resolution 4 - to approve the issue of the Options, Whitman Howard Warrants, Shakespeare Martineau Warrants and Existing Director Warrants (each as defined in the Prospectus);

 

· Resolution 5 - to change the name of the Company to Nuformix plc on completion of the Acquisition and the Placing (as defined in the Prospectus); and

 

· Resolution 6 - to disapply statutory pre-emption rights in respect of the issue and allotment of Ordinary Shares (as defined in the Prospectus) pursuant to (a) the New Ordinary Shares, Consideration Shares, Success Fee Shares, Convertible Loan Note Shares and Whitman Howard Fee Shares and (b) valid exercise of the Options and (c) valid exercise of the Whitman Howard Warrants, Shakespeare Martineau Warrants, Convertible Loan Note Warrants and Existing Director Warrants and (d) in addition, up to a further 46,075,000 Ordinary Shares.

 

Following the issue of the New Ordinary Shares, Consideration Shares, Success Fee Shares and Whitman Howard Fee Shares, the capital of the Company consists of 460,750,000 ordinary shares of 0.1 pence each, none of which are held in treasury. The total number of voting rights in the Company is, therefore, 460,750,000.

 

Application will shortly be made for the enlarged share capital to be admitted to the Official List and to trading on the main market of the London Stock Exchange. It is expected that admission will become effective and that trading will commence on 16 October 2017.

 

On Re-Admission, each of Dan Gooding, David Tapolczay, Joanne Holland and Kirk Siderman-Wolter will be appointed as directors of the Company and Pascal Hughes and Anthony Reeves will step down as directors of the Company.

 

The number of proxy votes received in relation to Resolution 1 were as follows:

 

Votes

Resolution 1

For

46,911,330 (100%)

Against

0 (0%)

Discretion of chairman

0 (0%)

Discretion of third party

0 (0%)

Withheld

0

 

 

 

The number of proxy votes received in relation to Resolution 2 were as follows:

 

Votes

Resolution 2

For

46,911,330 (100%)

Against

0 (0%)

Discretion of chairman

0 (0%)

Discretion of third party

0 (0%)

Withheld

0

 

 

The results of the poll in relation to Resolution 3 were as follows:

 

 

Votes

Resolution 3

For

46,548,343 (100%)

Against

0 (0%)

 

 

The number of proxy votes received in relation to Resolution 4 were as follows:

 

Votes

Resolution 4

For

46,798,343 (100%)

Against

0 (0%)

Discretion of chairman

0 (0%)

Discretion of third party

0 (0%)

Withheld

112,987

 

 

The number of proxy votes received in relation to Resolution 5 were as follows:

 

Votes

Resolution 5

For

46,911,330 (100%)

Against

0 (0%)

Discretion of chairman

0 (0%)

Discretion of third party

0 (0%)

Withheld

0

 

 

The number of proxy votes received in relation to Resolution 6 were as follows:

 

Votes

Resolution 6

For

46,801,325 (99.77%)

Against

110,005 (0.23%)

Discretion of chairman

0 (0%)

Discretion of third party

0 (0%)

Withheld

0

 

 

A copy of the resolutions passed at the above meeting will shortly be available for inspection on both Levrett plc's website (www.levrett.com), Nuformix Limited's website (www.nuformix.com) as well as at the National Storage Mechanism (www.morningstar.co.uk/uk/NSM).

 

If you have any queries or require further information, please contact:

 

Levrett plc

John Lidgey - Chairman

 

+44 (0)20 7183 4342

 

Whitman Howard Limited

Financial Advisor to Levrett plc

Nick Lovering

 

+44 (0)20 7659 1234

 

Gable Communications Ltd

Financial Public Relations

John Bick

Justine James

 

+44 (0)20 7193 7463

 

levrett@gablecommunications.com

 

 

Nuformix Limited

Dan Gooding - Chief Executive Officer

+44 (0)1223 423 667

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ROMGGGUWUUPMGGW
Date   Source Headline
19th Mar 20242:39 pmRNSResult of AGM
1st Mar 20247:00 amRNSSubscription to raise £150,000
15th Jan 202411:30 amRNSPosting of Annual Report and Notice of AGM
3rd Jan 20247:00 amRNSResults for the period ended 30 September 2023
18th Dec 20237:00 amRNSNXP001 Update
23rd Oct 20237:00 amRNSNotice of Allowance of NXP002 Patent in Japan
18th Sep 20237:00 amRNSNXP001 Update
24th Aug 20231:22 pmRNSResult of Annual General Meeting
31st Jul 20232:00 pmRNSNotice of AGM
26th Jul 20232:55 pmRNSHolding(s) in Company
2nd Jun 20237:00 amRNSInvestor Online Q&A
25th May 20237:00 amRNSChange of Auditor
22nd May 20237:00 amRNSUnaudited Interim Report
18th May 20237:00 amRNSNXP002 Inflammation and Duration of Action Update
26th Apr 202310:55 amRNSHolding(s) in Company
17th Apr 20237:00 amRNSSubscription to raise £70,000 & issue of Warrants
27th Mar 20237:00 amRNSNXP002 Update
13th Mar 20237:00 amRNSChange of Accounting Reference Date
15th Feb 20237:00 amRNSNXP002 Update
3rd Jan 20231:37 pmRNSHolding(s) in Company
20th Dec 20221:02 pmEQSNuformix hoping to 'initiate discussions with major pharma' in 2023
20th Dec 20227:00 amRNSNXP004 Update
13th Dec 20227:00 amRNSHalf-year Report
5th Dec 20227:00 amRNSResignation of Auditor
16th Nov 20228:50 amRNSHolding(s) in Company
4th Nov 20227:00 amRNSInvestor Webinar
23rd Sep 20227:00 amRNSNXP002 Update
23rd Sep 20227:00 amRNSNXP002 Update
25th Aug 20222:39 pmRNSResult of AGM
19th Aug 20228:57 amRNSHolding(s) in Company
10th Aug 20227:00 amRNSNXP002 Completion of Tolerability Studies
1st Aug 202212:13 pmRNSPosting of Annual Report and Notice of AGM
28th Jul 20227:01 amRNSBoard Changes
28th Jul 20227:00 amRNSAnnual Results for the year ended 31 March 2022
5th Jul 20227:00 amRNSNXP002 data to be presented at 2022 ERS Congress
29th Jun 20227:00 amRNSNXP004 Update
27th Jun 20227:00 amRNSNXP002 Update
20th Jun 20227:00 amRNSHolding(s) in Company
31st May 20227:00 amRNSDirectorate Change
30th May 20227:00 amRNSCorporate Update
12th Apr 20227:00 amRNSSecond tranche of Lanstead subscription shares
11th Apr 20223:54 pmRNSHolding(s) in Company
8th Apr 202211:21 amRNSHolding(s) in Company
7th Apr 20223:44 pmRNSHolding(s) in Company
5th Apr 20226:07 pmRNSHolding(s) in Company
28th Mar 20227:00 amRNSNXP004 Patent
2nd Mar 20227:00 amRNSAppointment of Dr Dan Gooding as Consultant
1st Mar 20227:00 amRNSChange of Auditor
14th Feb 20224:37 pmRNSHolding(s) in Company
8th Feb 20227:00 amRNSOxilio NXP-001 formulation development contract

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.